<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335699</url>
  </required_header>
  <id_info>
    <org_study_id>D3560L00053</org_study_id>
    <secondary_id>KREST</secondary_id>
    <nct_id>NCT00335699</nct_id>
  </id_info>
  <brief_title>Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome</brief_title>
  <official_title>A 6-Week, Randomised, Open-Label, Parallel Group, Multi-Centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Non-Diabetic Metabolic Syndrome Subjects With Raised LDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the effect of rosuvastatin 10mg with
      atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome
      after 6 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg in the percentage reduction of LDL-C in Subjects with metabolic syndrome after 6 weeks of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of this study are to compare the effects of rosuvastatin 10mg with atorvastatin 10mg in subjects with metabolic syndrome, after 6weeks of treatment, on:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bringing subjects to their established NCEP ATP III target goals for LDL-C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bringing subjects to their non-HDL target goal(based on NCEP-ATP III criteria)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifying other lipids and lipid ratios</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modifying inflammatory markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin resistance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment>370</enrollment>
  <condition>Hypercholesterolemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metabolic syndrome patient; Presence of 3 or more of the following:

               -  Abdominal obesity (waist circumference): men &gt; 90cm(36 inch), women &gt; 80cm(32
                  inch)

               -  Triglycerides ≥ 150 mg/dL (1.70 mmol/L)

               -  HDL-C: men &lt; 40 mg/dL (1.04 mmol/L), women &lt; 50 mg/dL (1.3 mmol/L)

               -  BP ≥130/≥85 mmHg or subject receiving anti-hypertensive treatment

               -  Fasting blood glucose 110 mg dL (6.11 mmol/L) - 125 mg/dL (6.94 mmol.L)

          -  Elevated LDL-C concentrations reported within 4 weeks of visit 1 as follows;

               -  ≥ 130 mg/dL (3.36 mmol/L) to &lt; 220 mg/dL (5.69 mmol/L) in statin naive subjects
                  (subjects who have not taken any lipid-lowering therapy known to affect LDL-C in
                  the 4 weeks prior to visit 1)

               -  ≥ 100 mg/dL (2.59 mmol/L) to &lt; 160 mg/dL (4.14 mmol/L) in subjects who have taken
                  a lipid lowering drug(s) within 4 weeks of visit 1

          -  Triglyceride levels &lt; 400 mg/dL (4.52 mmol/L)

          -  Women of childbearing potential should be using a medically acceptable form of
             chemical or mechanical contraception.

        Exclusion Criteria:

          -  History of known diabetes mellitus

          -  Use of anti-hyperglycaemic medication.

          -  History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in
             particular history of myopathy.

          -  No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is
             &lt;10%.

          -  History of heterozygous or homozygous familial hypercholesterolaemia or known type III
             hyperlipoproteinaemia (familial dysbetalipoproteinaemia).

          -  Active arterial disease such as unstable angina pectoris, myocardial infarction,
             transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery
             bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary
             lead in period

          -  Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) &gt; 1.5 times
             the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement
             therapy was initiated within 3 months of entry into dietary lead-in phase.

          -  Current active liver disease (alanine aminotransferase [ALT] &gt; 2 x ULN) or severe
             hepatic impairment.

          -  Unexplained serum CK &gt;3 times ULN (e.g. not due to recent trauma, intramuscular
             injections, heavy exercise, etc).

          -  Serum creatinine &gt; 176 umol/L (2.0 mg/dL)

          -  History of alcohol, or drug, abuse or both.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Korea Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DaeGu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>IkSan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>JeonJu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>JinJu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>KwangJu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2006</study_first_submitted>
  <study_first_submitted_qc>June 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2007</last_update_posted>
  <keyword>Hypercholesterolemia with nondiabetic metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

